Flex Pharma (FLKS) Competitors

I-Mab (NASDAQ:IMAB) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, community ranking, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Which has preferable valuation and earnings, IMAB or FLKS?

Flex Pharma has lower revenue, but higher earnings than I-Mab.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.27M	18.18	-$206.44M	N/A	N/A
Flex Pharma	$840K	15.63	-$21.92M	N/A	N/A

Do analysts rate IMAB or FLKS?

I-Mab presently has a consensus target price of $7.00, suggesting a potential upside of 858.77%. Given I-Mab's stronger consensus rating and higher possible upside, analysts clearly believe I-Mab is more favorable than Flex Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33
Flex Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders hold more shares of IMAB or FLKS?

38.4% of I-Mab shares are held by institutional investors. Comparatively, 14.4% of Flex Pharma shares are held by institutional investors. 22.1% of I-Mab shares are held by insiders. Comparatively, 7.6% of Flex Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more volatility and risk, IMAB or FLKS?

I-Mab has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Flex Pharma has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500.

Does the media refer more to IMAB or FLKS?

In the previous week, I-Mab had 3 more articles in the media than Flex Pharma. MarketBeat recorded 3 mentions for I-Mab and 0 mentions for Flex Pharma. I-Mab's average media sentiment score of 0.00 equaled Flex Pharma'saverage media sentiment score.

Company	Overall Sentiment
I-Mab	Neutral
Flex Pharma	Neutral

Does the MarketBeat Community favor IMAB or FLKS?

Flex Pharma received 301 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 73.23% of users gave Flex Pharma an outperform vote while only 64.52% of users gave I-Mab an outperform vote.

Company	Underperform	Outperform
I-Mab	Outperform Votes 60 64.52%	Underperform Votes 33 35.48%
Flex Pharma	Outperform Votes 361 73.23%	Underperform Votes 132 26.77%

Is IMAB or FLKS more profitable?

I-Mab has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. I-Mab's return on equity of 0.00% beat Flex Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Flex Pharma	-1,208.42%	-98.04%	-83.37%

Summary

I-Mab beats Flex Pharma on 12 of the 16 factors compared between the two stocks.